GLAM

twitterlinkedin

GLAM

Glass-Laser Multiplexed Biosensor

Differential cancer diagnosis takes place daily in clinical settings for a better monitoring of patient responses to existing treatments. However outcome of this diagnosis is today still poor. Moreover, current technology to measure biomarker levels is expensive and sophisticated. Most cancer biomarker analysis use blood or biological tissues as the main source of material. These biopsies must be analyzed in specialized laboratories incurring in some limitations: high cost; specialized personnel and equipment; large amounts of biological material; long outcome delivery time; time consuming processes.

Therefore it exist a real need and urgency to have new diagnostic devices that provide diagnosis, prognosis, and monitoring data faster and with exquisite ultra-sensitivity on time to take the appropriate decisions to improve personalized diagnosis and therapy. The aim of GLAM project is to provide an innovative device to fulfill these requirements using soluble biomarkers for personalized diagnosis and therapy monitoring. Specifically we will design and develop a new diagnostic tool to detect biomarkers from biofluids obtained in a noninvasive manner, specifically focusing to urine and to genitourinary cancers, to help oncologist to take better treatment decisions, approaching personalized medicine.

GLAM will develop an integrated device based on novel label-free photonic biosensors with ultra-sensitivity, simplicity of use, portability, multiplexing and low cost. GLAM capitalizes on the unprecedented sensitivity achieved using laser microring resonators to detect key biomarkers in tumor development and treatment. Point of Care of the device will be carried out by preclinical and clinical sample analysis of genitourinary cancer patients to warrant personalized medicine.

Importantly the GLAM unique technology will make the device also usable with other biofluids and might also be used to help physicians with other biomarker driven.

Project Budget: 4'835'586 €

LEITAT Budget: 692'633 €

Financial Framework: Horizon 2020

Contract number: 634928

Start Date: 01/05/2015

End Date: 30/04/2019

Partners:

Contact Manager: R. de Sousa

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634928. This publication reflects only the author’s views and the European Union is not liable for any use that may be made of the information contained therein.